Get the Stockscreener App
0.0334
41.20%
-0.0234
After Hours:
.03
-0.0034
-10.18%
Aditxt Inc stock is traded at $0.0334, with a volume of 116.39M.
It is down -41.20% in the last 24 hours and down -55.41% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.0568
Open:
$0.0375
24h Volume:
116.39M
Relative Volume:
1.62
Market Cap:
$2.64M
Revenue:
$212.10K
Net Income/Loss:
$-40.19M
P/E Ratio:
-0.000006
EPS:
-5313.2836
Net Cash Flow:
$-13.92M
1W Performance:
-35.15%
1M Performance:
-55.41%
6M Performance:
-99.81%
1Y Performance:
-99.98%
1-Day Range:
$0.033
$0.0375
1-Week Range:
$0.033
$0.0621
52-Week Range:
$0.033
$218.00
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Compare ADTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.0334 | 2.64M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Aditxt Inc Stock (ADTX) Latest News
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales - Benzinga
Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February - Benzinga
ADTX stock plunges to 52-week low, touches $0.04 By Investing.com - Investing.com Australia
ADTX stock plunges to 52-week low, touches $0.04 - Investing.com
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert - Benzinga India
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt shares fall on 1-for-250 reverse stock split - MSN
Aditxt announces 1-for-250 reverse stock split By Investing.com - Investing.com Australia
Aditxt announces 1-for-250 reverse stock split effective March 17 - TipRanks
Aditxt announces 1-for-250 reverse stock split - Investing.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aditxt, Inc. Announces Reverse Stock Split Plan - TipRanks
Major 1:250 Reverse Split Coming for Aditxt Stock: Key Details for Shareholders - StockTitan
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025 - Bluefield Daily Telegraph
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves - Financial Content
Aditxt advances autoimmune therapy ADI-100 toward trials - Investing.com Australia
Aditxt advances autoimmune therapy ADI-100 toward trials By Investing.com - Investing.com Canada
Aditxt’s Adimune to ship substances for product formulation of of ADI-100 - TipRanks
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S. - Quantisnow
Aditxt approves reverse stock split, adjourns special meeting By Investing.com - Investing.com Australia
Aditxt approves reverse stock split, adjourns special meeting - Investing.com India
Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Expands By 638.6% - Defense World
Stocks Under $1: PMAX PRSO ARBB KAVL to Watch in March 2025 – More Stocks Inside - Financial Content
Aditx Therapeutics stock hits 52-week low at $0.07 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.07 - Investing.com India
Is the Market Bullish or Bearish on Aditxt? - Benzinga
Such Is The Power Of Aditxt Inc (NASDAQ: ADTX) - Stocks Register
Aditxt Unveils Strategic Initiatives During Virtual Fireside Chat - Defense World
Financial Health Check: Examining Aditxt Inc (ADTX)’s Key Ratios - The Dwinnex
Aditxt, Inc. Discusses Pearsanta’s Planned IPO and Innovations - TipRanks
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - Asianet Newsable
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar? - Asianet Newsable
Aditxt subsidiary Persanta engages Dominary Securities for IPO - Yahoo Finance
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO By Investing.com - Investing.com Australia
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter By Investing.com - Investing.com Nigeria
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 - Lelezard
Aditxt Co's Unit Pearsanta Engaged Dominari Securities Llc As Lead Underwriter For Pearsanta's Planned IPO - Marketscreener.com
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO - Investing.com India
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter - Investing.com
Can This New DNA Cancer Test Disrupt the $20B Diagnostics Market? Pearsanta Unveils IPO Plans - StockTitan
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):